

Docket No.: RLL-492US

Serial No.: 10/598,051

## INFORMATION DISCLOSURE CITATION

Applicants: KUMAR et al.

Filed: 8/16/2006

Group:

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,019,398	5/28/1991	Daste	424	480	
	A2	6,419,953	7/16/2002	Qiu et al.	424	465	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
	B1	WO 03/103635	12/18/2003	PCT	A61K	9/22		
	B2	WO 2004/071421	8/26/2004	PCT	A61K			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Physicians' Desk Reference, 52nd Edition, page 521 (1998)
	C2	The Merck Index, Twelfth Edition, page 1691 (1996)
	C3	Qiu et al., "Once-a-Day Controlled-Release Dosage Form of Divalproex Sodium I: Formulation Design and <i>In Vitro/In Vivo</i> Investigations" <i>Journal of Pharmaceutical Sciences</i> , 92(6):1167 (2003)


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7.1.00

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. RLL-492US	
In Re Application of <b>KUMAR et al.</b>					
Application No. 10/598,051	Filing Date I.A. 2/18/2005	Examiner Unknown	Customer No. 26815	Group Art Unit Unknown	Confirmation No. 9553
Title: <b>EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF DIVALPROEX SODIUM</b>					
<p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>					



**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-492US

In re Application of: **KUMAR et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/598,051	I.A. 2/18/2005	Unknown	26815	Unknown	9553

Title: **EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF DIVALPROEX SODIUM**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))


- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**


**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
April 12, 2007 (Date)
 Signature of Person Mailing Correspondence
Christine Kenedy-Renner
_____ Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: April 12, 2007

William D. Hare, Esq.  
Reg. No. 44,739

CUSTOMER NO. 26815

CC: